News & Events
News & Events
Institut Pasteur Korea establishes a foundation for the new area of AI-driven phenomic-based drug discovery research.
2019-04-25
Institut Pasteur Korea establishes a foundation for the new area of AI-driven phenomic-based drug discovery research.
- Opened a global discussion to facilitate AI-based drug discovery in the 15th anniversary international symposium -
.jpg)
.jpg)
[Left] The 15th anniversary international symposium was held at the Auditorium of Institut Pasteur Korea on the 24th of Apr. [Right] The speakers of the symposium and the members of Institut Pasteur Korea are taking a commemorative photo.
Apr. 25, 2019, Pangyo, Rep. of Korea ㅣ Institut Pasteur Korea (CEO : Wang-Shick Ryu), a leading institute of infectious disease and translational research, announced that it successfully completed an international symposium, titled “Artificial Intelligence(AI)-driven phenomic-based drug discovery” on Apr. 24, 2019 in Pangyo, Gyeonggi Province. This symposium was attended by about 250 experts in bio and pharmaceutical industries and medical and academic fields.
To celebrate the 15th anniversary of Institut Pasteur Korea, the symposium was held with an aim of establishing a foundation for new area of AI-based drug discovery research by combining the PhenomicScreen, a core drug discovery technology platform of Institut Pasteur Korea, with the AI, a key technology of the 4th Industrial Revolution.
The PhenomicScreen, established by Institut Pasteur Korea in-house through the combination of bio-imaging, automation and platform technology, is an image based high-throughput screening technology that enables analysis and quantification of living cells infected with diseases and of genes. Utilizing the technology, researchers can identify new early-stage drug candidates and new drug targets more effectively and efficiently, thus leading to a higher possibility of successful drug discovery research.
Leveraging this technology platform resulted Institut Pasteur Korea successful development of new drug candidates, including the first-in class drug candidates to treat tuberculosis (Q203) and hepatitis C. In particular, 'Q203' was transferred to a spin-off bio-venture, Qurient Co. Ltd., established by Institut Pasteur Korea, for which the clinical phase 2 is currently underway.
Among the speakers of the symposium, Ulf Nehrbass, CEO of the Luxembourg Institute of Health and the first CEO of Institut Pasteur Korea, presented the latest research activities, entitled “AI and patient based drug discovery”, and Christophe Zimmer, Director of research of Cell biology and infections department of Institut Pasteur, talked about “Deep Learning for Imaging en masse & deep learning for the masses.” Wankyu Kim, Professor of Ewha Womans University, introduced new idea of “Assay Repositioning” and Woo Youn Kim, Professor of KAIST, shared the research status of “Drug discovery based on graph networks and deep generative models.”
In particular, Stewart Cole, a President of Director of Institut Pasteur, attended to the symposium to broaden the opportunities for international research collaboration of Korea the as well as to strengthen exchanges in the field of science and technology between Korea and France. Korea. Prof. Cole said, “Thanks to the continuous support of the Ministry of Science and ICT and the Gyeonggi Provincial Government, Institut Pasteur Korea has blossomed over the past 15 years into a regional powerhouse in infection biology and drug discovery technology” and continued “Institut Pasteur Korea has a particularly important role to play on the Korean peninsula within the global combat against anti-microbial resistance, a 21st-century public health challenge that is a strategic priority for the Institut Pasteur, and, as a member of the Institut Pasteur International Network located on 5 continents, Institut Pasteur Korea will serve as an important gateway for the Korean research community to exchange with the Network.”
The CEO of Institut Pasteur Korea, Wang-Shick Ryu, expressed, "Celebrating the 15th anniversary of Institut Pasteur Korea, we are pleased to invite the teachers and supporters who have helped Institut Pasteur Korea to become a global leader in infectious diseases and new drug discovery research," and added “Through this symposium, we will discuss the innovative strategies with global pioneers in the new research era of combining artificial intelligence and drug discovery to promote international cooperation and to strengthen R&D capability of Korea.”
Founded in 2004 with a goal of advancing national competence in drug development and R&D by fusing the IT technology of Korea with the BT technology of France, the Institut Pasteur Korea has been focusing on the discovery of new drug candidates to treat tuberculosis, super bacteria, new viruses and infectious diseases by utilizing an innovative drug discovery technology platform established in-house. Additionally, Institut Pasteur Korea is taking the initiative in fostering start-up through spin-off bio-venture establishment and bio-core facility establishment project.
About Institut Pasteur Korea
The Institut Pasteur Korea(IPK) is an international research institute with a basic research mission for infectious disease, and drug development to the benefit of public health. IPK was established in April 2004 in collaboration with Institut Pasteur Paris and the Korea Institute of Science and Technology(KIST), and is grateful for continous support from the Ministry of Science and ICT(MSIT), and the Gyeonggi Provincial govenment.
- Opened a global discussion to facilitate AI-based drug discovery in the 15th anniversary international symposium -
[Left] The 15th anniversary international symposium was held at the Auditorium of Institut Pasteur Korea on the 24th of Apr. [Right] The speakers of the symposium and the members of Institut Pasteur Korea are taking a commemorative photo.
Apr. 25, 2019, Pangyo, Rep. of Korea ㅣ Institut Pasteur Korea (CEO : Wang-Shick Ryu), a leading institute of infectious disease and translational research, announced that it successfully completed an international symposium, titled “Artificial Intelligence(AI)-driven phenomic-based drug discovery” on Apr. 24, 2019 in Pangyo, Gyeonggi Province. This symposium was attended by about 250 experts in bio and pharmaceutical industries and medical and academic fields.
To celebrate the 15th anniversary of Institut Pasteur Korea, the symposium was held with an aim of establishing a foundation for new area of AI-based drug discovery research by combining the PhenomicScreen, a core drug discovery technology platform of Institut Pasteur Korea, with the AI, a key technology of the 4th Industrial Revolution.
The PhenomicScreen, established by Institut Pasteur Korea in-house through the combination of bio-imaging, automation and platform technology, is an image based high-throughput screening technology that enables analysis and quantification of living cells infected with diseases and of genes. Utilizing the technology, researchers can identify new early-stage drug candidates and new drug targets more effectively and efficiently, thus leading to a higher possibility of successful drug discovery research.
Leveraging this technology platform resulted Institut Pasteur Korea successful development of new drug candidates, including the first-in class drug candidates to treat tuberculosis (Q203) and hepatitis C. In particular, 'Q203' was transferred to a spin-off bio-venture, Qurient Co. Ltd., established by Institut Pasteur Korea, for which the clinical phase 2 is currently underway.
Among the speakers of the symposium, Ulf Nehrbass, CEO of the Luxembourg Institute of Health and the first CEO of Institut Pasteur Korea, presented the latest research activities, entitled “AI and patient based drug discovery”, and Christophe Zimmer, Director of research of Cell biology and infections department of Institut Pasteur, talked about “Deep Learning for Imaging en masse & deep learning for the masses.” Wankyu Kim, Professor of Ewha Womans University, introduced new idea of “Assay Repositioning” and Woo Youn Kim, Professor of KAIST, shared the research status of “Drug discovery based on graph networks and deep generative models.”
In particular, Stewart Cole, a President of Director of Institut Pasteur, attended to the symposium to broaden the opportunities for international research collaboration of Korea the as well as to strengthen exchanges in the field of science and technology between Korea and France. Korea. Prof. Cole said, “Thanks to the continuous support of the Ministry of Science and ICT and the Gyeonggi Provincial Government, Institut Pasteur Korea has blossomed over the past 15 years into a regional powerhouse in infection biology and drug discovery technology” and continued “Institut Pasteur Korea has a particularly important role to play on the Korean peninsula within the global combat against anti-microbial resistance, a 21st-century public health challenge that is a strategic priority for the Institut Pasteur, and, as a member of the Institut Pasteur International Network located on 5 continents, Institut Pasteur Korea will serve as an important gateway for the Korean research community to exchange with the Network.”
The CEO of Institut Pasteur Korea, Wang-Shick Ryu, expressed, "Celebrating the 15th anniversary of Institut Pasteur Korea, we are pleased to invite the teachers and supporters who have helped Institut Pasteur Korea to become a global leader in infectious diseases and new drug discovery research," and added “Through this symposium, we will discuss the innovative strategies with global pioneers in the new research era of combining artificial intelligence and drug discovery to promote international cooperation and to strengthen R&D capability of Korea.”
Founded in 2004 with a goal of advancing national competence in drug development and R&D by fusing the IT technology of Korea with the BT technology of France, the Institut Pasteur Korea has been focusing on the discovery of new drug candidates to treat tuberculosis, super bacteria, new viruses and infectious diseases by utilizing an innovative drug discovery technology platform established in-house. Additionally, Institut Pasteur Korea is taking the initiative in fostering start-up through spin-off bio-venture establishment and bio-core facility establishment project.
About Institut Pasteur Korea
The Institut Pasteur Korea(IPK) is an international research institute with a basic research mission for infectious disease, and drug development to the benefit of public health. IPK was established in April 2004 in collaboration with Institut Pasteur Paris and the Korea Institute of Science and Technology(KIST), and is grateful for continous support from the Ministry of Science and ICT(MSIT), and the Gyeonggi Provincial govenment.